Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14183091 | 1.00 | MAP3K14 (0.67) | MAP3K14CA2CA5AMAOAMAOB | |
| SCHEMBL4366274 | 0.85 | MAP3K14 (0.53) | MAP3K14CA2CA5AMAOAMAOB | |
| SCHEMBL4347592 | 0.81 | CA2 (0.53) | MAP3K14CA2CA5AMAOAMAOB | |
| SCHEMBL21284745 | 0.81 | CA2 (0.53) | MAP3K14CA2CA5AMAOAMAOB | |
| SCHEMBL16137573 | 0.80 | MAP3K14 (0.65) | MAP3K14CA2CA5AKDM4EMEN1 | |
| SCHEMBL22143947 | 0.80 | MAP3K14 (0.65) | MAP3K14 | |
| SCHEMBL3556913 | 0.80 | MAP3K14 (0.65) | MAP3K14 | |
| SCHEMBL18998244 | 0.80 | MAOA (0.45) | MAP3K14CA2CA5AMAOAMAOB | |
| SCHEMBL12501454 | 0.80 | MAP3K14 (0.65) | MAP3K14MAOBMEN1MAPTKMT2A | |
| SCHEMBL20449183 | 0.80 | MAP3K14 (0.65) | MAP3K14MAOBMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-07 | — | — | US | disclosed |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
| EP-2278999-A2 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | Otonomy, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009132050-A2 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | MAP3K14 2556/4885CA2 4328/4885CA5A 4199/4885 |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | MAP3K14 2556/4885CA2 4328/4885CA5A 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.